Literature DB >> 15465561

Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.

J Raymond Buncic1, Carol A Westall, Carole M Panton, J Robert Munn, Leslie D MacKeen, William J Logan.   

Abstract

OBJECTIVE: To describe the clinical pattern of retinal atrophy in children caused by the anticonvulsant vigabatrin.
DESIGN: An interventional case series report. PARTICIPANTS: One hundred thirty-eight patients, mainly infants, were evaluated regularly for evidence of possible vigabatrin toxicity in the Eye and Neurology clinics at the Hospital for Sick Children, Toronto.
METHOD: Sequential clinical and electroretinographic (International Society for Clinical Electrophysiology of Vision standards) evaluations every 6 months. MAIN OUTCOME MEASURES: Presence of recognizable retinal and optic atrophy in the presence of abnormal electroretinogram (ERG) and other clinical findings.
RESULTS: Three children being treated for seizures with vigabatrin showed definite clinical findings of peripheral retinal nerve fiber layer atrophy, with relative sparing of the central or macular portion of the retina and relative nasal optic nerve atrophic changes. Some macular wrinkling was evident in 1 case. Progressive ERG changes showing decreased responses, especially the 30-Hz flicker response, supported the presence of decreased retinal function.
CONCLUSIONS: A recognizable and characteristic form of peripheral retinal atrophy and nasal or "inverse" optic disc atrophy can occur in a small number of children being treated with vigabatrin. The changes in superficial light reflexes of the retina in children facilitate the clinical recognition of nerve fiber layer atrophy. The macula is relatively spared, although superficial retinal light reflexes indicating wrinkling of the innermost retina suggest early macular toxicity as well. Because these changes are accompanied by electrophysiologic evidence of retinal dysfunction, discontinuation of vigabatrin should be strongly considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465561      PMCID: PMC3880364          DOI: 10.1016/j.ophtha.2004.03.036

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  26 in total

1.  Vigabatrin-induced optic neuropathy.

Authors:  K Crofts; R Brennan; P Kearney; G O'Connor
Journal:  J Neurol       Date:  1997-10       Impact factor: 4.849

2.  Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.

Authors:  E A Wilson; M J Brodie
Journal:  BMJ       Date:  1997-06-07

3.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

4.  Vigabatrin associated retinal dysfunction in children with epilepsy.

Authors:  R Koul; A Chacko; A Ganesh; S Bulusu; K Al Riyami
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

5.  The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.

Authors:  Carol A Westall; William J Logan; Kim Smith; J Raymond Buncic; Carole M Panton; Mohamed Abdolell
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

6.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

7.  Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy.

Authors:  D V Pow; W Baldridge; D K Crook
Journal:  Neuroscience       Date:  1996-08       Impact factor: 3.590

8.  Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

Authors:  G L Krauss; M A Johnson; N R Miller
Journal:  Neurology       Date:  1998-03       Impact factor: 9.910

9.  Electrophysiological assessment of contrast sensitivity in human infants.

Authors:  A M Norcia; C W Tyler; D Allen
Journal:  Am J Optom Physiol Opt       Date:  1986-01

10.  Vigabatrin in childhood epilepsy: a 5-year follow-up study.

Authors:  P Uldall; J Alving; L Gram; H Høgenhaven
Journal:  Neuropediatrics       Date:  1995-10       Impact factor: 1.947

View more
  23 in total

1.  Optical coherence tomography measurements in compressive optic neuropathy associated with dysthyroid orbitopathy.

Authors:  Kyung-Ah Park; Yoon-Duck Kim; Kyung In Woo; Changwon Kee; Jong Chul Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-12       Impact factor: 3.117

2.  Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.

Authors:  Betül Tuğcu; Mesrure Köseoğlu Bitnel; Fatma Selin Kaya; Betül Tekin Güveli; Dilek Ataklı
Journal:  Neurol Sci       Date:  2017-05-16       Impact factor: 3.307

3.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

Review 4.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 5.  OCT: New perspectives in neuro-ophthalmology.

Authors:  Gema Rebolleda; Laura Diez-Alvarez; Alfonso Casado; Carmen Sánchez-Sánchez; Elisabet de Dompablo; Julio J González-López; Francisco J Muñoz-Negrete
Journal:  Saudi J Ophthalmol       Date:  2014-10-05

6.  The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.

Authors:  John M Wild; Saleh Aljarudi; Philip E M Smith; Carlo Knupp
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

7.  Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.

Authors:  James D Akula; Emily R Noonan; Alessia Di Nardo; Tara L Favazza; Nan Zhang; Mustafa Sahin; Ronald M Hansen; Anne B Fulton
Journal:  Doc Ophthalmol       Date:  2015-03-12       Impact factor: 2.379

8.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

9.  Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.

Authors:  Qing-Ping Wang; Firas Jammoul; Agnès Duboc; Jie Gong; Manuel Simonutti; Elisabeth Dubus; Cheryl M Craft; Wen Ye; José A Sahel; Serge Picaud
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

10.  Contrast sensitivity is reduced in children with infantile spasms.

Authors:  Giuseppe Mirabella; Sharon Morong; J Raymond Buncic; O Carter Snead; William J Logan; Shelly K Weiss; Mohamed Abdolell; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.